A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Treatment With Single and Repeat Doses of Inhaled RV6153 in Healthy Subjects and Subjects With Stable Asthma.

Trial Profile

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Treatment With Single and Repeat Doses of Inhaled RV6153 in Healthy Subjects and Subjects With Stable Asthma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs RV 6153 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors RespiVert
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Mar 2016 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 13 Jan 2016 Planned End Date changed from 1 Apr 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top